Should You Buy GlaxoSmithKline plc As Sir Andrew Witty Retires?

Is the future looking brighter for investors in GlaxoSmithKline plc (LON:GSK)?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) today announced that chief executive Sir Andrew Witty will step down from the FTSE 100 pharma giant on 31 March next year.

Witty, who began as a management trainee with Glaxo 32 years ago, has been at the helm of the company since May 2008. However, speculation about the 51-year-old’s future has been rife for some time.

Criticism

Witty has faced criticism for falling sales and profits over the last few years, a less promising pipeline of medicines than some rivals and a bribery scandal in China.

Glaxo has also underperformed peers on shareholder returns. According to Bloomberg, the company’s average return has been 10% a year over the last five years, lagging well behind a 17% average annual return for the Bloomberg Europe Pharmaceutical Index.

Return to growth

Despite the travails of recent years, Glaxo is set to return to sales and core earnings growth in 2016. The company posted better-than-expected annual results last month, which Witty said showed that the strategy he’s been pursuing is paying off.

Today, he reiterated the “momentum of our current business performance” and the positive outlook, and said: “By next year, I will have been CEO for nearly 10 years and I believe this will be the right time for a new leader to take over”.

In last month’s results, Glaxo guided that it expects core earnings growth to reach double digits (at constant exchange rates) in 2016 and that its generous dividend will be maintained. At a current share price of just under £14, Glaxo trades on 16.5 times forecast earnings and offers a 5.7% dividend yield. In my opinion, these are attractive numbers for a company set to enter a new growth phase.

Break-up value

If Glaxo looks an appealing prospect in its current form, there’s also potential to deliver significant shareholder returns by breaking up the company. Glaxo’s four divisions of pharmaceuticals, consumer health products, vaccines and HIV medicines could be worth much more as standalone businesses than Glaxo’s current share price values them at.

A number of major shareholders see merit in the company going down this route. Richard Marwood, of Axa Investments, referring to Glaxo’s four divisions, has said: “If you had a blank piece of paper you would have never designed a drugs company like this”. And Marwood has been talking to Glaxo chairman Sir Philip Hampton about this “structural issue”.

Respected fund manager Neil Woodford and his team have also been outspoken on the subject, saying earlier this year: “All four of Glaxo’s major component businesses could be FTSE 100 companies in their own right, and we strongly believe that any future break-up would unlock considerable shareholder value”.

Win-win

Key changes in the boardroom can often be a precursor to major changes to the company. While the chairman said today that Glaxo “remains focused on execution of its strategy to drive growth and performance,” calls to unlock the value in the sum-of-the-parts of the group could intensify.

But, either way, whether Glaxo continues in its present form or is broken up, I reckon the shares are a good-value buy at around the £14 level.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Google office headquarters
Investing Articles

1 reason I like buying S&P 500 shares – and 1 reason I don’t

Will this investor try to improve his potential returns by focusing more on S&P 500 shares instead of British ones?…

Read more »

Young woman holding up three fingers
Investing Articles

3 SIPP mistakes to avoid

Our writer explains a trio of potentially costly errors he tries to avoid making when investing his SIPP, on an…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Here’s how (and why) I’d start buying shares with £25 a week

Our writer uses his investment experience and current approach to explain how he would start buying shares on a limited…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s my 5-step approach to earning passive income of £500 a month

Christopher Ruane explains the handful of steps he uses to target hundreds of pounds in passive income each month.

Read more »

Investing Articles

2 UK shares I’ve been buying this week

From a value perspective, UK shares look attractive. But two in particular have been attracting Stephen Wright’s attention over the…

Read more »

Investing Articles

A lifelong second income for just £10 a week? Here’s how!

With a simple, structured approach to buying blue-chip dividend shares at attractive prices, our writer's building a second income for…

Read more »

Investing Articles

Here’s how I’d use a £20k Stocks and Shares ISA to help build generational wealth

Discover how our writer would aim to turn a £20k Stocks and Shares ISA into a sizeable nest egg by…

Read more »